InsiderClue
Insiders · Profile

Kirchgraber Paul R

CEO, Covance Drug Development at Labcorp. Filing since 4 Nov 2020. CIK 0001791393

Company
Date
Role
Action
Shares
Amount
Of holding
LH Labcorp
19 May 2023
CEO, Covance Drug Development
Sold at will
4,300
$932.71K
24.9%
LH Labcorp
21 Feb 2023
CEO, Covance Drug Development
Sold, plan not stated
8,000
$2.00M
46.9%
LH Labcorp
6 May 2021
CEO, Covance Drug Development
Sold, plan not stated
2,500
$691.38K
24.2%
LH Labcorp
4 Nov 2020
CEO, Covance Drug Development
Sold, plan not stated
1,500
$321.20K
16.3%
4 decisions on file.